Repeat Faecal Immunochemical Testing for Colorectal Cancer Detection in Symptomatic and Screening Patients: A Systematic Review and Meta-Analysis
Cancers · 19.09.2024 · 16 (18) · 3199
DOI: 10.3390/cancers16183199 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.09.2024. Verfasst von Adam D Gerrard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh EH4 2XR, UK. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Bowel Cancer UK and the Royal College of Surgeons of Edinburgh, Scottish Government.
Abstract (Originalsprache)
Background
Faecal immunochemical testing (FIT) is widely used in bowel screening programmes and assessing symptomatic patients for suspected colorectal cancer (CRC). The evidence for single test performance of FIT in both settings is considerable; however, the use of a repeat test to increase sensitivity remains uncertain. We aimed to review what increase in test positivity would be generated by additional FITs, whether a repeated FIT detects previously missed CRC and advanced colorectal neoplasia (ACRN), and to estimate the sensitivity of double-FIT strategies to diagnose CRC and ACRN.
Methods
A systematic search of MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) was performed using key search terms. Studies reporting the use of more than one FIT in the same screening round or planned assessment of a single symptomatic patient episode were included. Studies were categorised by the reported study population into asymptomatic, mixed (cohorts of combined asymptomatic, symptomatic, or high-risk surveillance), or symptomatic cohorts.
Results
A total of 68 studies were included for analysis (39 asymptomatic, 21 mixed, 7 symptomatic, and 1 study with discrete asymptomatic and symptomatic data). At a threshold of 10 µg Hb/g, the two-test positivity ranged between 8.1 and 34.5%, with an increase from the second test of 3–9.2 percentage points. Four out of five studies comparing one versus two tests for diagnosing CRC at 10 µg Hb/g identified additional cases with the second test, with a minimum of 50% reduction in missed CRC. At a threshold of 20 µg Hb/g, the second test increased the positivity by 1.3–6.7 percentage points, with a two-test positivity of between 5.1 and 25.0%. Using a threshold of 20 µg Hb/g, five out of seven studies had a 25% reduction in missed CRC. A meta-analysis estimated the double-FIT sensitivity at 10 µg Hb/g for CRC in mixed-risk and symptomatic cohorts to be 94% and 98%, respectively.
Conclusions
Repeated use of FIT helps to diagnose more cases of CRC with a moderate increase in positivity. A double-FIT strategy at 10 µg Hb/g in mixed and symptomatic cohorts has a very high sensitivity for CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh EH4 2XR, UK.
- Department of Colorectal Surgery, Western General Hospital, Edinburgh EH4 2XU, UK.
- Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh EH4 2XR, UK.
- School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow G12 8QQ, UK.
- Department of Surgery, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.
- UK Colon Cancer Genetics Group, Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics & Cancer, Western General Hospital, The University of Edinburgh, Edinburgh EH4 2XU, UK.
ORCID-Profile: Adam D Gerrard, Farhat V N Din
Förderung
- Cancer Research UK
- Bowel Cancer UK and the Royal College of Surgeons of Edinburgh
- Scottish Government
- Chief Scientist Office
- Bowel Cancer UK
- Royal College of Surgeons of Edinburgh
- Cancer Research UK programme
- CRUK Career Development Fellowship
Zitieren
APA
Gerrard, A. D., Garau, R., Xu, W., Maeda, Y., Dunlop, M. G., Theodoratou, E., & Din, F. V. N. (2024). Repeat Faecal Immunochemical Testing for Colorectal Cancer Detection in Symptomatic and Screening Patients: A Systematic Review and Meta-Analysis. Cancers, 16(18), 3199. https://doi.org/10.3390/cancers16183199
Vancouver
Gerrard AD, Garau R, Xu W, Maeda Y, Dunlop MG, Theodoratou E, et al. Repeat Faecal Immunochemical Testing for Colorectal Cancer Detection in Symptomatic and Screening Patients: A Systematic Review and Meta-Analysis. Cancers. 2024;16(18):3199. doi:10.3390/cancers16183199
BibTeX
@article{Gerrard2024,
author = {Gerrard, Adam D and Garau, Roberta and Xu, Wei and Maeda, Yasuko and Dunlop, Malcolm G and Theodoratou, Evropi and Din, Farhat V N},
title = {Repeat Faecal Immunochemical Testing for Colorectal Cancer Detection in Symptomatic and Screening Patients: A Systematic Review and Meta-Analysis},
journal = {Cancers},
year = {2024},
volume = {16},
number = {18},
pages = {3199},
doi = {10.3390/cancers16183199}
}
EUVIMED